Skip to Content

Brokerages have assigned a consensus rating of “Moderate Buy” to ShockWave Medical, Inc. (NASDAQ:SWAV).

Brokerages have assigned a consensus rating of “Moderate Buy” to ShockWave Medical, Inc. (NASDAQ:SWAV).

ShockWave Medical, Inc. (NASDAQ: SWAV), which ten different rating agencies cover, has been given an average rating of “Moderate Buy” by these agencies, as reported by Bloomberg. This evaluation was derived from the stock price of the company. Research analysts have made seven recommendations regarding the stock: six recommendations to buy the stock, two to maintain ownership, and one to sell the stock. This stock is expected to reach an average price target of $250.89 over the next year, according to projections made by brokerage firms. In addition, these companies have assigned a rating to the stock in the most recent twelve months.
A growing number of research companies have expressed interest in SWAV throughout the past few months. On December 16, Deutsche Bank Aktiengesellschaft published a research note announcing it would begin covering ShockWave Medical. The note was released on Friday. They suggested that investors purchase the stock and establish a price objective of $285.00. On December 16, Deutsche Bank Aktiengesellschaft published a research note announcing it would begin covering ShockWave Medical. The note was released on Friday. They suggested that investors purchase the stock and establish a price objective of $285.00. Bank of America announced on November 7, in a research report published on November 7, that they would be increasing their price objective for ShockWave Medical from $260.00 to $310.00. Morgan Stanley lowered their price objective for ShockWave Medical from $290.00 to $224.00 in a research note distributed on Friday.
Additionally, an “equal weight” rating was given to the stock by the company. In a research note released on December 12, Wells Fargo & Company concluded that their price objective for ShockWave Medical should be reduced from $300 to $235. Additionally, the firm lowered its rating for the company from “overweight” to “equal weight” for the stock.
According to earlier ShockWave Medical news, Chief Financial Officer Dan Puckett sold 1,100 shares of the company’s stock on Thursday, October 20. This information was made public by the company. The sale of the stock resulted in total revenue of $295,185.00, with the average price at which each share could be purchased being $268.35. Because of the sale, the chief financial officer now owns 39,938 shares. Based on the current market price of those shares, the CFO’s stake is approximately worth $10,717,362.30. The sale was made known to the general public through a document initially submitted to the SEC and then made available online by the SEC. In addition, Isaac Zacharias, a company management team member, sold 4,000 shares of the company’s stock on Tuesday, December 27. This comes in the wake of other recent developments concerning the company. The sale of the shares resulted in total revenue of $838,360, with the average price at which each share could be purchased being $209.59. Following the completion of the transaction, the company insider now possesses 73,021 shares of the company, which have a combined value of $15,304,471.39. Should you follow this link, you will be taken to the SEC filing in which the transaction was discussed in greater detail. In addition, on October 20, Dan Puckett, the company’s Chief Financial Officer, sold 1,100 shares of the company’s stock. The sale of the stock resulted in total revenue of $295,185.00, with the average price at which each share could be purchased being $268.35. Because of the transaction, the chief financial officer now owns 39,938 of the company’s shares, which have a combined value of $10,717,362. 30. Disclosures that are related to the sale might be found in this section of the website. Over the most recent three months, company insiders have generated total revenue of $12,615,504 by selling 51,300 shares of the company’s stock. Currently, company insiders own 3.90 percent of the total stock in the company.
Due to recent occurrences, hedge funds and institutional investors have modified their company stock holdings and taken new positions. During the third quarter, Tobam made an investment in ShockWave Medical valued at $32,000. During the second quarter of the fiscal year, CWM LLC increased its holdings in ShockWave Medical by 219.7%. CWM LLC now has a total of 195 shares, valued at $37,000, thanks to the fact that it made additional purchases of 134 shares of the company during the period in question. In addition, Shockwave Medical received an investment contribution from PenderFund Capital Management Ltd. for $41,000 during the year’s first three months. During the second quarter, First Horizon Advisors Inc. increased the amount of ShockWave Medical stock owned by 3,666.7% to bring its total ownership percentage to 100%. First Horizon Advisors Inc. now has 226 shares, valued at $43,000, after purchasing an additional 220 shares over time. These shares were purchased as part of a series of purchases. Lastly, but certainly not least, during the second quarter, Private Capital Group LLC increased the percentage of ShockWave Medical, in which it has an interest, by 42.0%. Private Capital Group LLC currently owns 257 shares of the company’s stock, collectively worth $49,000. This is a result of the company’s acquisition of 76 additional shares during the relevant period. The company’s stock is currently owned by institutional investors and hedge funds, who account for 90.56 percent of the company’s ownership.
On Friday, the NASDAQ: SWAV stock started the trading day with a price of $208.21. The current share price of ShockWave Medical is $113.36, which represents the stock’s 52-week low. The stock’s current price of $320.54 represents its 52-week high. This corporation has a beta value of 1.04, a price-to-earnings ratio of 89.36, and a market capitalization of $7.52 billion. This stock’s moving average for the past 50 days is currently sitting at $238.02, and its moving average for the past 200 days is currently at $248.43. There is a current ratio of 7.29, a quick ratio of 6.02, and a debt-to-equity ratio of 6.02. The debt-to-equity ratio is at 0.04, and the quick ratio is at 6.02.
The financial results report for ShockWave Medical, publicly traded on the NASDAQ under the symbol SWAV, was made available to the public on November 7. The company reported earnings per share (EPS) for the period at $0.92, which is $0.24 higher than the average estimate of $0.68 per share. As evidenced by their high return on equity (30.08%) and their healthy net margin (20.48%), ShockWave Medical did very well. In addition, the revenue for the quarter came in significantly higher than the $125.85 million analysts had anticipated, coming in at a total of $131.33 million instead. According to the forecasts provided by equity research analysts, ShockWave Medical should be able to generate earnings of $2.93 per share for the current financial year.
ShockWave Medical, Inc. develops and markets technology for intravascular lithotripsy to treat calcified plaque in patients all over the world with peripheral vascular, coronary vascular, or heart valve conditions. Catheters with the designation M5 are utilized in treating peripheral artery disease (PAD) above the knee, catheters with the designation C2 are utilized in treating coronary artery disease, and catheters with the designation S4 are utilized in the treatment of PAD below the knee.

Tags

Leave a comment

Your email address will not be published. Required fields are marked *